辅助中医药降低精神分裂症患者再住院风险:台湾全国队列研究
基于台湾全民健康保险研究数据库2000至2021年200万人代表性队列,纳入18至65岁新诊断精神分裂症患者,经1:1倾向评分匹配后4578例。中药使用者定义为接受门诊中药治疗超过28天。结果显示中药组精神分裂症相关再住院风险显著较低(调整风险比0.601;95%CI 0.482-0.863;p<0.001),且平均住院时间更短、5年累计精神科入院次数更少。结论认为辅助中医药与更好的长期结局相关,支持将中医药纳入标准精神科照护的潜在价值。
要点
- 辅助中医药与精神分裂症患者5年再住院风险显著降低相关(aHR 0.601)。
- 中药组平均住院时间更短,5年累计精神科入院次数更少。
- 中药使用定义为门诊中药治疗超过28天,需进一步前瞻性研究验证。
核心结论
- 辅助中医药使用与精神分裂症患者更好的长期结局相关,支持将中医药纳入标准精神科照护的潜在价值。
研究设计与样本
- 数据来自台湾全民健康保险研究数据库中的纵向世代追踪数据库(LGTD),为2000至2021年200万人代表性队列。
- 纳入18至65岁新诊断精神分裂症患者,经排除标准及1:1倾向评分匹配后选取4578例。
- 中药使用者定义为接受门诊中药治疗超过28天。
主要发现
- 中药组精神分裂症相关再住院风险显著较低(调整风险比=0.601;95%CI 0.482-0.863;p<0.001)。
- 中药组平均住院时间更短。
- 中药组5年累计精神科入院次数更少。
关键数值与推荐
- 中药使用者定义为接受门诊中药治疗超过28天。
- 再住院风险调整风险比=0.601;95%CI 0.482-0.863;p<0.001。
临床怎么用
- 在标准精神科治疗基础上,可考虑联合中医药治疗超过28天以改善长期结局。
- 对精神分裂症患者应关注再住院风险、住院时间及累计入院次数,辅助中医药可能带来获益。
局限性
- 原文为观察性队列研究,需进一步前瞻性研究验证结果并阐明机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Schizophrenia is a chronic psychiatric disorder marked by high relapse and rehospitalization rates. Although antipsychotic medications are effective, their adverse effects frequently compromise treatment adherence. Traditional Chinese medicine (TCM) is widely used as a complementary therapy in Taiwan, but real-world evidence regarding its long-term effectiveness remains limited. METHODS: Data were obtained from the Longitudinal Generation Tracking Database (LGTD), a two-million representative cohort within Taiwan's National Health Insurance Research Database (NHIRD) spanning 2000 to 2021. Patients aged 18-65 years with newly diagnosed schizophrenia were identified. Following the application of exclusion criteria and 1:1 propensity score matching, 4578 patients were selected. TCM users were defined as those who received outpatient Chinese herbal medicine for >28 days. Outcomes included 5-year rehospitalization risk, length of stay (LOS), and admission frequency. RESULTS: The TCM group exhibited a significantly lower risk of schizophrenia-related rehospitalization (adjusted hazard ratio = 0.601; 95% CI, 0.482-0.863; p < 0.001). They also had shorter average LOS and fewer cumulative psychiatric admissions over 5 years. CONCLUSIONS: Adjunctive TCM use was associated with better long-term outcomes in patients with schizophrenia. These findings support the potential value of incorporating TCM into standard psychiatric care. Further prospective studies are warranted to validate these results and elucidate the mechanisms contributing to these effects.
引用
- Soong WT, Chung CH, Tzeng NS, et al. Effectiveness of adjunctive traditional Chinese medicine in reducing psychiatric rehospitalization in patients with schizophrenia: A nationwide cohort study in Taiwan. Integr Med Res. 2026. PMID: 41778076. doi:10.1016/j.imr.2026.101306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。